Luitpold Animal Health, manufacturers of Adequan products, issued an update Sept. 16 indicating that while Adequan IM has slowly begun returning to the market, the drug will remain in short supply for a time. The company announced in May that they expected supply shortages due to factory renovations at their Shirley, N.Y., facility, and supplies have been limited throughout the late spring and summer.
"We are pleased to announce a shipment of Adequan IM was released to the market last week and was received by veterinarians beginning Friday, Sept. 13," the Sept. 16 statement read. "Adequan product supply remains limited, and the initial shipments will not fully satisfy market demand. Luitpold made significant investments in upgrading its manufacturing facilities earlier this year. The time spent making these upgrades impacted our ability to keep up with demand. We are working diligently to release additional product to the market and will provide updates as they become available. "
Luitpold encouraged Adequan users "to continue to work with their veterinarians to obtain the drug and discuss the most appropriate treatment regimen for your animals."
Adequan (polysulfated glycosaminoglycan) was approved by the Food and Drug Administration for equine use in 1984 and is designed to treat non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal (knee) and hock joint